Allergan plc (AGN)
(Delayed Data from NYSE)
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
WIll Allergan (AGN) Beat Estimates This Earnings Season?
by Zacks Equity Research
Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q3 as loss of exclusivity of several products hurts sales.
Is a Beat in the Cards for Mallinckrodt (MNK) in Q3 Earnings?
by Zacks Equity Research
Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q3 results.
Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.
Is a Beat in the Cards for Regeneron (REGN) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports third-quarter 2019 results.
Mylan (MYL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers, when Mylan (MYL) reports Q3 results along with updates on merger with Upjohn.
Allergan (AGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie's (ABBV) Q3 sales may have been weighed down by biosimilar competition for Humira in international markets. However, strong growth of oncology drugs might have offset impact of Humira's international sales erosion.
Will Allergan (AGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
J&J (JNJ) Recalls Baby Powder Batch as FDA Finds Asbestos
by Zacks Equity Research
J&J (JNJ) voluntarily recalls one lot of its baby powders, which is the subject of numerous lawsuits claiming that its talc-based products contain asbestos that causes cancer.
Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow
by Kinjel Shah
FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3
Editas Inks Deal for Gene Editing Neurological Disease Drugs
by Zacks Equity Research
Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
Allergan (AGN) Shareholders Approve Acquisition by AbbVie
by Kinjel Shah
Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.
Johnson & Johnson's (JNJ) Legal Problems Continue to Worry Investors
by Christopher Vargas
Johnson & Johnson (JNJ) is set to report their third quarter results as pending lawsuits loom over the company.
Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
by Zacks Equity Research
Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.
Wet AMD Space in Focus: New Drug Approvals & Key Advancements
by Ekta Bagri
The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.
J&J Settles Ahead of Multi-District Opioid Trial, Stock Up
by Zacks Equity Research
J&J (JNJ) reaches settlement agreement with Cuyahoga and Summit counties in Ohio concerning the lawsuits pending in MDL.
Allergan (AGN) Stock Moves -1.09%: What You Should Know
by Zacks Equity Research
In the latest trading session, Allergan (AGN) closed at $166.46, marking a -1.09% move from the previous day.
IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA
by Zacks Equity Research
IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.
Allergan (AGN) Stock Moves -0.1%: What You Should Know
by Zacks Equity Research
In the latest trading session, Allergan (AGN) closed at $166.69, marking a -0.1% move from the previous day.
The Zacks Analyst Blog Highlights: Bristol-Myers, Lockheed, Alphabet, Allergan and Kinder Morgan
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Lockheed, Alphabet, Allergan and Kinder Morgan
FDA Warns About Safety of Breast Implant: 3 Stocks at Risk (Revised)
by Zacks Equity Research
As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.
Top Analyst Reports for Bristol-Myers Squibb, Lockheed Martin & Alphabet
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb (BMY), Lockheed Martin (LMT) and Alphabet (GOOGL).
Ironwood Amends Linzess Agreement with AstraZeneca in China
by Zacks Equity Research
Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.
FDA Warns About Safety of Breast Implant: 3 Stocks at Risk
by Sreyoshi Mukherjee
As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.
Allergan (AGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Allergan (AGN) closed at $165.56 in the latest trading session, marking a -0.35% move from the prior day.